Novel Model Effectively Predicts Early Relapse After CAR-T Therapy in Myeloma

A novel prognostic model has been developed to help determine the timing of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory multiple myeloma (MM). The model aims to predict early relapse to CAR-T therapy, which is associated with increased mortality risk. The model, called Myeloma CAR-T Relapse (MyCARe), considers factors such as extramedullary disease, lenalidomide refractoriness, high-risk cytogenetics, and high ferritin levels. The model effectively predicts the 5-month relapse rate and can help optimize patient selection for CAR-T therapy in this challenging population. The study included data from 269 patients and showed comparable outcomes between European and American cohorts.

Source link

error: Content is protected !!